Researcher index

Authors in the psilocybin and psilocin literature

Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.

Zeller Matthias

41 indexed publications match this author name.

ORCID: Not found in stored metadata
OpenAlex: Not found in stored metadata

Author watchlist

Create a confirmed email alert for new publications matching this author.

Topics

Pharmacology 18 Healthy Volunteers 12 Depression 11 Receptor Pharmacology 9 Anxiety 8 Mechanism of Action 7 Safety 7 Addiction 7 General 6 Consciousness 5 Mystical Experience 5 Clinical Trial 5

Journals

Journal of psychopharmacology (Oxford, England) 4 Clinical pharmacology and therapeutics 3 Neuroscience applied 3 Neuropsychopharmacology 2 Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 2 Psychopharmacology 2 Neuroscience Applied 2 Nature Communications 1

Publication history

Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networksNature Communications · 2026-08-03 Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participantsNeuropsychopharmacology · 2026-07-01 Acute Effects of 4-Bromo-2,5-Dimethoxyphenethylamine (2C-B) Compared With Psilocybin and MDMA in Healthy ParticipantsBiological Psychiatry · 2026-05-01 Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled SettingsRepository for Publications and Research Data (ETH Zurich) · 2026-04-30 An international mega-analysis of psychedelic drug effects on brain circuit function.Nature medicine · 2026-04-01 Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness-a psychometric analysis using the PES100 in controlled psychedelic studiesReligion Brain & Behavior · 2026-03-31 Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial.Clinical pharmacology and therapeutics · 2025-06-01 A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.Psychedelic medicine (New Rochelle, N.Y.) · 2025-03-01 Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program.Neuroscience applied · 2025-01-01 Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response.Journal of psychopharmacology (Oxford, England) · 2024-10-01 Structural characterization and comparative analysis of polymorphic forms of psilocin (4-hydroxy-N,N-dimethyltryptamine)Acta Crystallographica Section E Crystallographic Communications · 2024-06-01 Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2024-05-01 In vitro and in vivo metabolism of psilocybin’s active metabolite psilocinFrontiers in Pharmacology · 2024-04-29 Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.Scientific reports · 2024-03-26 The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.Journal of psychopharmacology (Oxford, England) · 2024-01-01 Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects.Neuroscience applied · 2024-01-01 Safety pharmacology of acute psilocybin administration in healthy participants.Neuroscience applied · 2024-01-01 Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2023-10-01 Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats.Molecular psychiatry · 2023-09-01 Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants.Clinical pharmacology and therapeutics · 2023-04-01 Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.Journal of psychopharmacology (Oxford, England) · 2023-01-01 Classic psychedelics do not affect T cell and monocyte immune responses.Frontiers in psychiatry · 2023-01-01 Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants.Psychopharmacology · 2022-06-01 Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2022-05-01 Psilocybe mexicana R. Heim - Mexikanischer KahlkopfZeitschrift für Phytotherapie · 2022-04-01 Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.Clinical pharmacology and therapeutics · 2022-04-01 Comparison of subjective, autonomic, and endocrine effects of LSD and psilocybin in healthy subjectsNeuroscience Applied · 2022-01-01 Pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of oral psilocybin administration in healthy subjectsNeuroscience Applied · 2022-01-01 Psychedelic use predicts objective knowledge about climate change via increases in nature relatednessDrug Science Policy and Law · 2022-01-01 New Insights Into the Clinical and Nonclinical Effects of Psychedelic SubstancesEuropean Psychologist · 2021-09-17 New insights into the clinical and nonclinical effects of psychedelic substances: an integrative reviewPsyArXiv · 2021-05-05 Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin’s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasmaJournal of Chromatography B · 2021-02-01 MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogensNeuropsychopharmacology · 2020-11-19 Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings.Proceedings of the National Academy of Sciences of the United States of America · 2020-02-04 P.228 The polypharmacological profile of psilocybin and potential behavioural effects of very low dosesEuropean Neuropsychopharmacology · 2019-12-01 Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness.Journal of psychopharmacology (Oxford, England) · 2017-08-01 Alterations of consciousness and mystical-type experiences after acute LSD in humans.Psychopharmacology · 2017-05-01 Synthesis, hydrolysis and stability of psilocin glucuronideForensic Science International · 2014-04-01 The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case seriesCephalalgia · 2010-03-26 Development of a psilocin immunoassay for serum and blood samplesInternational Journal of Legal Medicine · 2004-12-01 Synthesis of a psilocin hapten and a protein-hapten conjugateJournal of Pharmacy and Pharmacology · 2002-09-01

Author directory